Stock Market & Financial Investment News

News Breaks February 22, 2013 08:05 EDT TEVA Teva says additional QNASL data to be presented at AAAAI meeting Teva Pharmaceutical announced that additional data analyzed from the Phase III clinical program for QNASL Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology in San Antonio, Texas on February 22-26. Data will be presented at the meeting regarding the efficacy of QNASL in treating the symptoms associated with seasonal and perennial allergic rhinitis, including the drug’s potential quality of life benefits and sleep quality improvement. Furthermore, the data also demonstrated nasal symptom relief in patients with SAR and PAR who received treatment with QNASL 24 hours after dosing. On March 23, 2012, the U.S. Food and Drug Administration approved QNASL. The product became available by prescription in April 2012. News For TEVA From The Last 14 Days Check below for free stories on TEVA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 06:11 EDT TEVA Teva settles lawsuit, agrees to specify executive pay, Bloomberg reports Subscribe for More Information June 17, 2013 13:20 EDT TEVA Supreme Court rules generic drug makers can be sued over 'pay to delay' Subscribe for More Information 11:54 EDT TEVA Supreme Court ruling a modest negative for generics, says Leerink Subscribe for More Information 09:31 EDT TEVA Teva acquires MicroDose Therapeutx Subscribe for More Information 07:25 EDT TEVA Leerink to host a conference Subscribe for More Information June 14, 2013 08:06 EDT TEVA Teva says studies further define utility of Azilect in Parkinson’s treatment Teva Pharmaceutical announced that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson’s Disease and Movement Disorders in Sydney, Australia, June 16-20, also known as the Movement Disorders Society. “The AZILECT abstract topics presented at MDS demonstrate our efforts to further clarify the clinical utility of rasagiline to prescribers and PD patients across various stages of the disease,” said Michael Hayden, MD, President of Global R&D and Chief Scientific Officer at Teva. June 12, 2013 08:28 EDT TEVA Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix Subscribe for More Information 08:23 EDT TEVA Teva, Active Biotech announces results of Phase IIa study of laquinimod Subscribe for More Information 08:09 EDT TEVA Teva's Laquinimod for lupus reports positive Phase II results Subscribe for More Information 08:02 EDT TEVA Pfizer wins $2.15B settlement from Teva and Sun for patent infringement Subscribe for More Information 07:08 EDT TEVA Drugstores ready access changes to Plan B pill, WSJ reports Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, reports the Wall Street Journal.Reference Link 06:05 EDT TEVA On the Fly: Periodicals Wrap-Up WALL STREET JOURNAL: The tectonic plates of the world economy are shifting, moving the yield on the 10-year Treasury to the highest level in more than a year and shaking financial markets. Now, some constants are being questioned in markets, triggering paroxysms in stocks, bonds, commodities and the currencies of emerging markets, the Wall Street Journal reports...Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, the Wall Street Journal reports...REUTERS: If currency turbulence in emerging markets becomes a full-scale investor flight, the Fed may have a new headache in deciding when to slow its dollar printing policy. The link between U.S. monetary policy and currency runs on the other side of the world could be tighter than many assume, Reuters reports...Toyota Motor (TM) said it’s unlikely to recapture its peak market share it held four years ago in the U.S. (GM, F), its biggest market, the latest sign the carmaker is shifting to improving quality from aggressively expanding sales, Reuters reports...BLOOMBERG: Exchange executives (NYX, NDAQ), long shielded from legal scrutiny in the U.S., have been put on notice that may be changing after federal regulators fined CBOE Holdings (CBOE) $6M for unprecedented lapses in supervision, Bloomberg reports...Borealis Infrastructure Management and its Kuwaiti-British partners abandoned their $8.3B bid for the U.K. water utility Severn Trent (SVTRY) as the offer deadline expired, Bloomberg reports. June 11, 2013 05:50 EDT TEVA U.S. to now comply with ruling on morning-after pill, WSJ reports In a reversal, the U.S. government said it would allow emergency contraceptive Plan B to be sold in drugstores without restrictions and would end an appeal in a long-running court case, reports the Wall Street Journal. Reference Link June 10, 2013 07:20 EDT TEVA Biomed to host a conference Subscribe for More Information June 6, 2013 08:30 EDT TEVA Federal appeals court orders access to contraceptive, WSJ reports Subscribe for More Information 07:33 EDT TEVA Teva Laquinimod could become $1B franchise, says Bernstein Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.